80wk Uptrend — rising+above (sma 17.83 vs px 24.20)
Funds Accumulating — momZ +2.75 · 2.97→3.30
Founder-Led — founder/CEO led
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: December 8, 2017
Headquarters: 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Founder-Led: Yes — Ryan Watts (Co-Founder, President, CEO & Director), Alexander Schuth (Co-Founder, CFO, COO & Secretary)
Key Metrics
Current Price
$24.93
Market Cap
$3.99B
Float
155.1M
Shares Outstanding
159.8M
Price/Sales (TTM)
1,106.60
vs. Analyst Target
+42.1% to analyst PT
Operating Margin (TTM)
-3601.30%
Revenue (TTM)
$3.6M
Dividend Rate
None
Analyst Target Price
$35.44 (19 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$336M
$71.1M
$336M
$71.2M
2021
$48.7M
-$291M
$48.7M
-$287M
2022
$108M
-$326M
$108M
-$316M
2023
$331M
-$145M
$331M
-$128M
2024
N/A
-$423M
-$7.8M
-$493M
2025
N/A
-$513M
-$11.2M
-$498M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
N/A
-$127M
Dec 2025
N/A
-$129M
Mar 2026
N/A
-$128M
Jun 2026
$3.6M
-$128M
Ownership & Float
Insider Ownership
9.1%
Institutional Ownership
101.3%
Short Float
11.2%
% of All Funds Holding
3.30%
Number of Funds Holding
290
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$24.56
Near-term / short-term trend
Weekly
40-Week SMA
$20.77
Medium-term trend
Weekly
80-Week SMA
$17.84
Cyclical trend (business cycle)
Weekly
200-Week SMA
$21.49
Secular trend (multi-year)
Monthly
10-Month SMA
$21.15
Near-term monthly trend
Monthly
20-Month SMA
$18.44
Medium-term monthly trend
Monthly
40-Month SMA
$20.56
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$20.80
support
1.17x
1 months ago
Historical Earnings Reactions (35 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.14%
0.10%
51.43%
9.58%
-5.61%
1 Day
-1.07%
-1.38%
42.86%
13.97%
-15.06%
1 Week
-1.49%
-3.59%
28.57%
24.68%
-18.83%
2 Weeks
-1.11%
-3.97%
40.00%
24.91%
-18.55%
1 Month
0.95%
0.13%
50.00%
46.03%
-33.92%
Next earnings: October 25, 2026 (59 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
6.9%
55.6%
9
Feb
-2.3%
33.3%
9
Mar
-8.8%
22.2%
9
Apr
0.8%
55.6%
9
May
5.6%
77.8%
9
Jun
7.8%
66.7%
9
Jul
-5.3%
33.3%
9
Aug
6.7%
62.5%
8
Sep
2.2%
50.0%
8
Oct
-3.7%
37.5%
8
Nov
13.7%
62.5%
8
Dec
1.1%
37.5%
8
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.03%
46.1%
410
Tuesday
0.33%
52.3%
451
Wednesday
0.34%
51.5%
447
Thursday
-0.25%
44.3%
440
Friday
0.02%
47.5%
438
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 101.3%
Insider Transactions — Smart Summary
Total insider ownership: 9.1%
Founder-led management: Ryan Watts (Co-Founder, President, CEO & Director), Alexander Schuth (Co-Founder, CFO, COO & Secretary)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Denali Therapeutics Inc
(DNLI) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.